New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way.
The National Institutes of Health announced Thursday that it is launching the safety trial on a...
Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline has received...
Health Canada says it has approved a plan by GlaxoSmithKline to fix contamination problems it...
A Briton and an American were sentenced to prison on Friday on charges of illegally trading in the personal details of Chinese citizens after they testified they bought such information to help companies combat fraud.
A British man on trial with his American wife for illegally obtaining and selling private information about Chinese nationals says he buys such information from other consulting companies. Peter William Humphrey made the comments Friday after his trial opened in Shanghai.
A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."
The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.
GSK CEO Sir Andrew Witty and CFO Simon Dingemans on the group’s Q2 2014 results and strategy update.
A recent Health Canada inspection of the country's only flu vaccine production plant identified 10 issues that need to be addressed, a report from the regulatory agency reveals. The summary report of the June inspection said none of the problems found poses a critical risk to public health, but seven fall into the major observation category.
GlaxoSmithKline and Theravance today announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).
Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.
A U.S. Embassy spokesman says diplomats are barred from the trial in Shanghai of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information. Spokesman Nolan Barkhouse said Friday that the U.S. government is concerned about lack of access to the trial of Yu Yingzeng and husband Peter Humphrey in August.
GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it marketed drugs for uses unapproved by federal regulators. Lawsuits filed in 44 states and the District of Columbia alleged that the British drugmaker misrepresented the uses and qualities of its asthma drug Advair and the antidepressants Paxil and Wellbutrin.
Britain's Serious Fraud Office says it has opened a criminal investigation into the commercial practices of GlaxoSmithKline PLC and its subsidiaries. The company has faced a series of investigations into its activities in recent months including a major corruption probe in China.
Pernix Therapeutics Holdings has signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet® (sumatriptan/naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.
Chinese police have accused a British executive of GlaxoSmithKline of leading a sprawling scheme to bribe doctors and hospitals to use its drugs. The announcement was the first time a foreign employee in China of British-based GSK was accused in the investigation announced last July.
Ligand Partner GSK Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic AnemiaApril 30, 2014 8:01 am | News | Comments
Ligand Pharmaceuticals has announced that the FDA has granted its partner GlaxoSmithKline Priority Review designation for Promacta™/Revolade™ (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.
Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.
GlaxoSmithKline and Genmab A/S announced that the FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate.
British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company said Wednesday that it started looking into the conduct of "a small number of individuals" in December. It says the investigation is ongoing.
The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The agency cleared the company's drug, Tanzeum, to help patients control their blood sugar levels, in combination with diet and exercise.
The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. A "Panorama" show to air Monday evening quotes a former sales representative for the company saying doctors there were paid to prescribe its drugs.
GlaxoSmithKline is recalling the weight loss drug Alli after receiving reports of unknown pills and tablets in the bottles.
Mylan has announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GSK relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.
Agenus Inc. announced that GlaxoSmithKline’s MAGRIT i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon ® adjuvant, did not meet its first or second co-primary endpoint.
- Page 1